The Mitochondria-Targeted Methylglyoxal Sequestering Compound, MitoGamide, Is Cardioprotective in the Diabetic Heart.

Mitchel TateGavin C HigginsMiles J De BlasioRuna LindblomDarnel PrakosoMinh DeoHelen KiriazisMin ParkCarlos D Baeza-GarzaStuart T CaldwellRichard C HartleyThomas KriegMichael P MurphyMelinda T CoughlanRebecca Helen Ritchie

Published in: Cardiovascular drugs and therapy (2020)

Our findings suggest that MitoGamide, a novel mitochondria-targeted approach, offers cardioprotection in experimental diabetes and therefore may offer therapeutic potential for the treatment of cardiomyopathy in patients with diabetes.

Keyphrases

type diabetes
heart failure
cancer therapy
cell death
cardiovascular disease
reactive oxygen species
endoplasmic reticulum
glycemic control
atrial fibrillation
drug delivery
combination therapy
insulin resistance
replacement therapy